Trenbolone Acetate
A potent 19-nor androgen originally developed for cattle, never approved for human use. Produces dramatic recomposition alongside the heaviest side-effect burden of any compound in common use.
01 Overview
Trenbolone binds the androgen receptor with very high affinity and does not aromatise, giving strong anabolic and nutrient-partitioning effects. It has no human clinical data — the profile below is drawn from veterinary pharmacology, case reports, and consistent user experience, which is why its research score is low despite how widely it is discussed.
It is not a reasonable early compound; its risk profile is categorically worse than testosterone.
02 Mechanism
High-affinity androgen-receptor agonist that does not aromatise but is progestogenic, and raises prolactin. Strong nutrient partitioning toward lean tissue is the effect users seek.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Common | 150–300 mg/wk | IM | Even experienced users rarely exceed the low end; it is far stronger than the dose implies. |
| High | 300–500 mg/wk | IM | Side-effect burden rises steeply; not advisable. |
Ester comparison
| Ester | Half-life | Injection freq. | Testosterone by mass |
|---|
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Rapid recompositionSimultaneous lean gain and fat loss, consistently reported | Marked | Anecdotal | |
| Increased strengthReported disproportionate to the dose | Marked | Anecdotal | |
| Nutrient partitioningEstablished in livestock; not studied in humans | Strong | Preclinical |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Sleep disruption and night sweatsInsomnia and heavy sweating, among the most consistently reported effects. | Moderate | Very common | Anecdotal | |
| Cardiovascular and mood effectsRaised blood pressure, adverse lipid shifts, anxiety and aggression reported more than with testosterone. | Severe | Common | Observational |